Clinical Trial Update: B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma [Phase 1]

View source ↗

Summary

A Phase 1 study is investigating a B7H3/IL13Ra2 bispecific armored CAR T-cell therapy for recurrent or refractory glioblastoma. The trial is currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• B7H3/IL13Ra2 Bispecific Armored CAR T-Cell Therapy

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Refractory Glioblastoma, Recurrent Glioblastoma | Phase 1 | Status: RECRUITING